Head-to-head trials are the rarest and most useful thing in this space. Most phase 3 trials compare a new compound against placebo, which tells you a drug works but not how it stacks up against what people are already using. Lilly just dropped the answer to a question the community has been asking for years: what happens when you put retatrutide, the triple agonist, directly against the highest approved dose of Ozempic?
The results landed overnight, and they are not subtle.
What the trial was
TRANSCEND-T2D-2 was a phase 3 study that enrolled 1,298 adults with type 2 diabetes and compared once-weekly retatrutide at 9 mg or 12 mg against once-weekly injectable Ozempic at 2 mg, the highest approved dose of semaglutide for type 2 diabetes in most markets. The trial ran for 80 weeks, and unlike the usual placebo-controlled design, it was open-label, meaning participants and researchers knew who was getting what. That matters for interpretation, because knowing your assignment can influence how people report symptoms, though it cannot manufacture an A1C number or a difference in weight.
The primary endpoint was A1C reduction, and the design tested whether retatrutide 12 mg was non-inferior to Ozempic 2 mg. It was not just non-inferior. It cleared the bar and kept going.
What the Research Says
- Both retatrutide doses (9 mg and 12 mg) lowered A1C by an average of 2.2 percentage points over 80 weeks, from a baseline of 8.3%, compared with 1.8 percentage points for Ozempic 2 mg, meeting the primary endpoint and all key secondary endpoints.
- Weight loss was where the gap widened: retatrutide 9 mg produced an average loss of 19.5% and 12 mg produced 20.9%, against 9.4% for Ozempic 2 mg. That is more than double the weight reduction on a baseline body weight of about 102 kg.
- Treatment discontinuation due to adverse events was higher with retatrutide, at 4.8% for the 9 mg dose and 7.9% for the 12 mg dose, compared with 2.7% for Ozempic. Diarrhoea, nausea and vomiting were the most common side effects reported.
- Retatrutide remains investigational and is not approved anywhere. Lilly has indicated a regulatory filing is planned for the first quarter of 2027.
Why the weight numbers matter more than the A1C numbers
An A1C difference of 2.2% versus 1.8% is real but modest. Both are strong results, and the typical starting A1C of 8.3% means both groups ended up in a range that most clinicians would call well controlled. If you looked at the glycaemic numbers alone, you would shrug and say the drugs are comparable.
The weight numbers are a different story. A 20.9% average loss at 80 weeks in a type 2 diabetes population is remarkable, because people with type 2 diabetes historically lose less weight on GLP-1 medications than people without diabetes. The 20.8% figure Lilly reported for the 12 mg dose in TRIUMPH-2, published in the Lancet last week, is consistent with what we saw in that trial. The 9.4% for Ozempic 2 mg is roughly in line with what semaglutide has shown in this population across its own trials, so this is not an unusually weak comparator.
The likely explanation is mechanism. Retatrutide is a triple agonist, activating GLP-1, GIP and glucagon receptors, where Ozempic is GLP-1 only. The glucagon arm in particular is thought to drive energy expenditure effects that pure GLP-1 agonism does not deliver. Our retatrutide research page covers the mechanism and the trial history in detail, and the tirzepatide page is useful context for how the dual agonists performed on the same questions.
The caveats worth holding onto
The open-label design is the first caveat. Direct head-to-head trials in this field are rare precisely because they are expensive and logistically hard, but the trade-off is that everyone knew what they were taking. Side effect reporting in particular can be influenced by expectation.
The second caveat is the discontinuation rate. Roughly one in twelve people on retatrutide 12 mg quit the trial because of side effects, versus about one in thirty-seven on Ozempic. The pattern is consistent across the entire retatrutide programme: more efficacy, more gastrointestinal burden, more people leaving. That trade-off is the honest story of this compound class, and it does not show up in the headline percentage.
Third, and this is worth repeating: retatrutide is not approved anywhere. It is an investigational compound, the results are a corporate announcement of topline data rather than a peer-reviewed publication, and the detailed breakdown will be presented at a future medical meeting. Anyone encountering retatrutide vials for sale online right now is looking at an unapproved product with no regulatory oversight, which is exactly the counterfeit and grey-market problem the TGA keeps warning about.
What this means for the pipeline race
Lilly called TRANSCEND-T2D-2 the sixth phase 3 trial in which retatrutide has delivered positive results, and the company is guiding toward a regulatory filing in the first quarter of 2027. If that timeline holds, the triple agonist class arrives while the dual agonist market is already crowded and the single agonist market is commoditising.
For the community, the interesting question is not whether retatrutide is the strongest weight-loss compound yet tested in type 2 diabetes, because the numbers suggest it is. The interesting question is whether the additional glucagon mechanism justifies the tolerability trade-off at the individual level, and that is a question the trial data can only partially answer. People respond differently, and the aggregate numbers hide the spread.
The Grey Highway Telegram group is where the community is picking apart the trial details, and given how fresh this announcement is, the topline-versus-detailed-data conversation is already well underway.
Sources
Source: Eli Lilly and Company, “Lilly’s retatrutide delivered greater A1C reduction and more than double the weight loss of Ozempic’s highest approved dose in head-to-head trial”, 28 October 2026: https://investor.lilly.com/news-releases/news-release-details/lillys-retatrutide-delivered-greater-a1c-reduction-and-more
Source: Clinical Trials Arena, “Lilly’s retatrutide beats Ozempic in head-to-head trial”, 28 October 2026: https://www.clinicaltrialsarena.com/news/lillys-retatrutide-beats-ozempic-in-head-to-head-trial/
Source: RTTNews via Nasdaq, “Lilly’s Retatrutide Outperforms Ozempic In Phase 3 Diabetes Trial”, 28 October 2026: https://www.nasdaq.com/articles/lillys-retatrutide-outperforms-ozempic-phase-3-diabetes-trial
Disclaimer: This article is for educational and informational purposes only. It does not constitute medical advice, therapeutic recommendations, or endorsements of any compound. Grey Highway is a research-education community. We do not sell, supply, or promote the use of research compounds. Always consult a qualified healthcare professional regarding health decisions. For Australian regulatory information, visit the TGA website.